Insmed sales and marketing update

Insmed said its inventory for amyotrophic lateral sclerosis (ALS) drug iPlex mecasermin rinfibate is fully depleted. The company said about 10 patients remain on the drug. Insmed is evaluating potential out-licensing opportunities for the complex of insulin-like growth factor-1 ( IGF-1) and its principal binding protein (IGFBP3). Details were not disclosed. ...